Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Molecular and Cellular Biology
|
January 20, 2011
The chaperone network connected to human ribosome-associated complex
Himjyot Jaiswal, Charlotte Conz, Hendrik Otto, et al.
The Journal of Biological Chemistry
|
September 29, 2007
Functional characterization of the atypical Hsp70 subunit of yeast ribosome-associated complex
Charlotte Conz, Hendrik Otto, Kristin Peisker, et al.
BMC Medical Research Methodology
|
October 8, 2022
Joint analysis of PK and immunogenicity outcomes using factorization model - a powerful approach for PK similarity study
Halimu N Haliduola, Fausto Berti, Heimo Stroissnig, et al.
Expert Opinion on Investigational Drugs
|
May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL) in healthy male adults
Monika Tomaszewska-Kiecana, Felicitas Bullo, Lukasz Jaskiewicz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 9, 2005
The chaperones MPP11 and Hsp70L1 form the mammalian ribosome-associated complex
Hendrik Otto, Charlotte Conz, Philipp Maier, et al.
Expert Opinion on Investigational Drugs
|
May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (60 mg/mL) in healthy male adults
Anel Pretorius, Felicitas Bullo, Lukasz Jaskiewicz, et al.
Expert Opinion on Biological Therapy
|
July 12, 2023
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis
Steven R Feldman, Nataliya Reznichenko, Fausto Berti, et al.
Expert Opinion on Biological Therapy
|
October 5, 2022
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults
Christopher Wynne, Christian Schwabe, Heimo Stroissnig, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
May 19, 2023
Assessing the Interchangeability of AVT02 and Humira<sup>®</sup> in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study
Steven R Feldman, Richard Kay, Nataliya Reznichenko, et al.
Expert Opinion on Investigational Drugs
|
February 2, 2022
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)
Christopher Wynne, Christian Schwabe, Charlotte Lemech, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Molecular and Cellular Biology
|
January 20, 2011
The chaperone network connected to human ribosome-associated complex
Himjyot Jaiswal, Charlotte Conz, Hendrik Otto, et al.
The Journal of Biological Chemistry
|
September 29, 2007
Functional characterization of the atypical Hsp70 subunit of yeast ribosome-associated complex
Charlotte Conz, Hendrik Otto, Kristin Peisker, et al.
BMC Medical Research Methodology
|
October 8, 2022
Joint analysis of PK and immunogenicity outcomes using factorization model - a powerful approach for PK similarity study
Halimu N Haliduola, Fausto Berti, Heimo Stroissnig, et al.
Expert Opinion on Investigational Drugs
|
May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL) in healthy male adults
Monika Tomaszewska-Kiecana, Felicitas Bullo, Lukasz Jaskiewicz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 9, 2005
The chaperones MPP11 and Hsp70L1 form the mammalian ribosome-associated complex
Hendrik Otto, Charlotte Conz, Philipp Maier, et al.
Expert Opinion on Investigational Drugs
|
May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (60 mg/mL) in healthy male adults
Anel Pretorius, Felicitas Bullo, Lukasz Jaskiewicz, et al.
Expert Opinion on Biological Therapy
|
July 12, 2023
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis
Steven R Feldman, Nataliya Reznichenko, Fausto Berti, et al.
Expert Opinion on Biological Therapy
|
October 5, 2022
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults
Christopher Wynne, Christian Schwabe, Heimo Stroissnig, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
May 19, 2023
Assessing the Interchangeability of AVT02 and Humira<sup>®</sup> in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study
Steven R Feldman, Richard Kay, Nataliya Reznichenko, et al.
Expert Opinion on Investigational Drugs
|
February 2, 2022
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)
Christopher Wynne, Christian Schwabe, Charlotte Lemech, et al.
Page
of 2